{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:21Z","timestamp":1790352561016,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06406-4","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:55:54Z","timestamp":1766084154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-5699","authenticated-orcid":false,"given":"Keitaro","family":"Shimozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-5775","authenticated-orcid":false,"given":"Akira","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"6406_CR1","doi-asserted-by":"publisher","first-page":"9651","DOI":"10.1038\/s41467-025-65148-6","volume":"16","author":"EJ Carstens","year":"2025","unstructured":"Carstens EJ, Takahashi K, Sakamoto N, De Vizio M, Morgado M, Nikkhoi SK, Mangipudi A, Nguyen CH, Weltzin T, Nakayama I, Lv Q, Zeng J, Nie C, Deng C, Wang X, Liu L, Klempner SJ, Ramasubramanian A, Nowak JA, Aguirre AJ, Shitara K, Smith EL (2025) Modeling and addressing on-target\/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat Commun 16:9651. https:\/\/doi.org\/10.1038\/s41467-025-65148-6","journal-title":"Nat Commun"},{"key":"6406_CR2","unstructured":"European Medicine Agency (2024) Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/glossary-terms\/summary-product-characteristics. Accessed date month 2025"},{"key":"6406_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"6406_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/nejmoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048. https:\/\/doi.org\/10.1056\/nejmoa071834","journal-title":"N Engl J Med"},{"key":"6406_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10120-024-01566-7","volume":"28","author":"H-D Kim","year":"2025","unstructured":"Kim H-D, Shin J, Hyung J, Lee H, Moon M, Ma J, Park YS, Ryu M-H (2025) Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression. Gastric Cancer 28:74\u201382. https:\/\/doi.org\/10.1007\/s10120-024-01566-7","journal-title":"Gastric Cancer"},{"key":"6406_CR6","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.c.6861193.v1","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee K-W, Shitara K, Metges J-P, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai L-Y, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang Y-J, Shah MA (2023) Data from ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2\u2013positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 29:3882\u20133891. https:\/\/doi.org\/10.1158\/1078-0432.c.6861193.v1","journal-title":"Clin Cancer Res"},{"key":"6406_CR7","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S, Nakamura Y, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Yoshino T, Kuwata T, Shitara K (2023) Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8:100762. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762","journal-title":"ESMO Open"},{"key":"6406_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K (2024) Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol 21:354\u2013369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2","journal-title":"Nat Rev Clin Oncol"},{"key":"6406_CR9","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/mcb.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, Kimura S (2001) Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol 21:7380\u20137390. https:\/\/doi.org\/10.1128\/mcb.21.21.7380-7390.2001","journal-title":"Mol Cell Biol"},{"key":"6406_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","volume":"8","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8:173\u2013181. https:\/\/doi.org\/10.1007\/s11523-013-0257-x","journal-title":"Target Oncol"},{"key":"6406_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24:1181\u20131195","journal-title":"Lancet Oncol"},{"key":"6406_CR12","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.ccr-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C, T\u00fcreci O (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624\u20137634. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-1547","journal-title":"Clin Cancer Res"},{"key":"6406_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, Jerling M, Utsch M, Rohde C, Dhaene K, Huber C, T\u00fcreci \u00d6 (2018) A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer 100:17\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2018.05.007","journal-title":"Eur J Cancer"},{"key":"6406_CR14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Shah MA, Shitara K, Ajani JA, Bang Y-J, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu R-H et al (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat Med"},{"key":"6406_CR15","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.esmogo.2025.100257","volume":"10","author":"K Shimozaki","year":"2025","unstructured":"Shimozaki K, Ooki A, Fukuoka S, Hirasawa T, Takamatsu M, Kawachi H, Wakatsuki T, Yoshikawa K, Yoshino K, Udagawa S, Osumi H, Ogura M, Shinozaki E, Chin K, Yamaguchi K (2025a) Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution? ESMO Gastrointest Oncol 10:100257. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100257","journal-title":"ESMO Gastrointest Oncol"},{"key":"6406_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmogo.2024.100128","volume":"7","author":"K Shimozaki","year":"2025","unstructured":"Shimozaki K, Ooki A, Yamahata Y, Aoyama T, Yoshino K, Tamba M, Udagawa S, Fukuoka S, Osumi H, Wakatsuki T, Shinozaki E, Ogura M, Chin K, Yamaguchi K (2025b) Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice. ESMO Gastrointest Oncol 7:100128. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100128","journal-title":"ESMO Gastrointest Oncol"},{"key":"6406_CR17","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1111\/cas.15684","volume":"114","author":"K Shitara","year":"2023","unstructured":"Shitara K, Kawazoe A, Hirakawa A, Nakanishi Y, Furuki S, Fukuda M, Ueno Y, Raizer J, Arozullah A (2023a) Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma. Cancer Sci 114:1606\u20131615. https:\/\/doi.org\/10.1111\/cas.15684","journal-title":"Cancer Sci"},{"key":"6406_CR18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/s0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu R-H, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang Y-K, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA (2023b) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668. https:\/\/doi.org\/10.1016\/s0140-6736(23)00620-7","journal-title":"Lancet"},{"key":"6406_CR19","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/nejmc2409512","volume":"391","author":"K Shitara","year":"2024","unstructured":"Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang Y-K, Lonardi S, Hung Y-P, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu R-H (2024a) Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma. N Engl J Med 391:1159\u20131162. https:\/\/doi.org\/10.1056\/nejmc2409512","journal-title":"N Engl J Med"},{"key":"6406_CR20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","volume":"27","author":"K Shitara","year":"2024","unstructured":"Shitara K, Xu R-H, Ajani JA, Moran D, Guerrero A, Li R, Pavese J, Matsangou M, Bhattacharya P, Ueno Y, Wang X, Shah MA (2024b) Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Gastric Cancer 27:1058\u20131068. https:\/\/doi.org\/10.1007\/s10120-024-01518-1","journal-title":"Gastric Cancer"},{"key":"6406_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396:635\u2013648. https:\/\/doi.org\/10.1016\/s0140-6736(20)31288-5","journal-title":"Lancet"},{"key":"6406_CR22","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/s0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY, Smyth EC (2025) Gastric cancer. Lancet 405:2087\u20132102. https:\/\/doi.org\/10.1016\/s0140-6736(25)00052-2","journal-title":"Lancet"},{"key":"6406_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"\u00d6 T\u00fcreci","year":"2011","unstructured":"T\u00fcreci \u00d6, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, Seitz G, Sahin U (2011) Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 481:83\u201392. https:\/\/doi.org\/10.1016\/j.gene.2011.04.007","journal-title":"Gene"},{"key":"6406_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M (2019a) A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol 30:1487\u20131495. https:\/\/doi.org\/10.1093\/annonc\/mdz199","journal-title":"Ann Oncol"},{"key":"6406_CR25","doi-asserted-by":"publisher","first-page":"1523096","DOI":"10.1080\/2162402x.2018.1523096","volume":"8","author":"\u04e6 T\u00fcreci","year":"2019","unstructured":"T\u00fcreci \u04e6, Mitnacht-Kraus R, W\u00f6ll S, Yamada T, Sahin U (2019b) Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 8:1523096. https:\/\/doi.org\/10.1080\/2162402x.2018.1523096","journal-title":"Oncoimmunology"},{"key":"6406_CR26","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1200\/jco.2011.40.9243","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 30:2861\u20132868. https:\/\/doi.org\/10.1200\/jco.2011.40.9243","journal-title":"J Clin Oncol"},{"key":"6406_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00543","volume":"8","author":"R Waters","year":"2024","unstructured":"Waters R, Sewastjanow-Silva M, Yamashita K, Abdelhakeem A, Iwata KK, Moran D, Elsouda D, Guerrero A, Pizzi M, Vicentini ER, Shanbhag N, Ta A, Chatterjee D, Ajani JA (2024) Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma. JCO Precis Oncol 8:2300543. https:\/\/doi.org\/10.1200\/po.23.00543","journal-title":"JCO Precis Oncol"},{"key":"6406_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2147\/ITT.S494696","volume":"4","author":"Y Wu","year":"2025","unstructured":"Wu Y, Tian J, Zhou Y, Zhang R, Gao X, Luo L (2025) High-affinity monoclonal antibody targeting Claudin18.2. Immunotargets Ther 4:189\u2013203","journal-title":"Immunotargets Ther"},{"key":"6406_CR29","doi-asserted-by":"publisher","first-page":"70280","DOI":"10.1111\/cts.70280","volume":"18","author":"A Yamada","year":"2025","unstructured":"Yamada A, Takeuchi M, Komatsu K, Bonate PL, Poondru S, Yang J (2025) Population PK and exposure-response analyses of zolbetuximab in patients with locally advanced unresectable or metastatic G\/GEJ adenocarcinoma. Clin Transl Sci 18:70280. https:\/\/doi.org\/10.1111\/cts.70280","journal-title":"Clin Transl Sci"},{"key":"6406_CR30","doi-asserted-by":"publisher","first-page":"105805","DOI":"10.1016\/j.esmoop.2025.105805","volume":"10","author":"K Yamamoto","year":"2025","unstructured":"Yamamoto K, Owaki Y, Nakayama I, Yamamoto K, Owaki Y, Nakayama I, Sakamoto N, Ishizaka M, Kadota T, Okemoto D, Matsubara Y, Miyashita Y, Kobayashi A, Okazaki U, Seguchi K, Hosokai T, Ogura T, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Kuboki Y, Bando H, Kojima T, Yoshino T, Kuwata T, Ishii G, Yano T, Shitara K et al (2025) Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer. ESMO Open 10:105805. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105805","journal-title":"ESMO Open"},{"key":"6406_CR31","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/jjco\/hyaf055","volume":"55","author":"Y Yanagimoto","year":"2025","unstructured":"Yanagimoto Y, Yamamoto K, Hara K, Masuike Y, Ushimaru Y, Kitamura M, Honma K, Matsuura N, Sugase T, Kanemura T, Mori R, Kitakaze M, Amisaki M, Kubo M, Mukai Y, Komatsu H, Sueda T, Kagawa Y, Nishimura J, Wada H, Goto K, Yasui M, Omori T, Miyata H (2025) Two cases of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer. Jpn J Clin Oncol 55:825\u2013831. https:\/\/doi.org\/10.1093\/jjco\/hyaf055","journal-title":"Jpn J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06406-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:55:57Z","timestamp":1766084157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06406-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6406"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06406-4","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures were performed in accordance with the Helsinki Declaration of 1964 and its later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived with the opportunity to opt out from the research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"16"}}